Mohali: An unpaved, badly damaged stretch of road in Phase 7 turned into a major traffic hazard after three two-wheeler ...
Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no ...
Primary composite endpoint met: 61% of patients achieved visual and pathological response across all treated lesions.Complete clinical and pathological response in 56% of high-risk head & neck ...
The highest dose group of EP-104GI (Cohort 9) demonstrated durability of symptom responses out to 52 weeks, with 66% of ...
Eli Lilly (LLY) and Viking Therapeutics (VKTX) delivered back-to-back clinical wins in the same week — one pushing the ...
Pharmacokinetic (PK) results reflected target-mediated drug disposition (TMDD) at low concentrations, confirming TX2100’s ...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a biopharmaceutical company dedicated to the discovery, development, manufacturing, ...
FDA Single IRB Rule for multisite trials advances to final rule status in December 2026, ending parallel IRB review for ...
Nice to meet you, I'm Miumi.I'm part of a family of five—my husband and our three children—and this year marks exactly 10 ...
Ayal Aizer, MD, MHS, discusses patients for whom single-fraction SRS may remain reasonable after brain metastasis resection.
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been enrolled in COMPASSION-37 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results